The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics

• Main Authors: Hiu Ting Chan, Yoon Ming Chin, Siew-Kee Low
• Format: Article
• Language: English
• Published: Adis, Springer Healthcare 2019-01-01
• Series: Oncology and Therapy
• Subjects: Cancer precision medicine; Germline variants; Next generation sequencing; Pharmacogenomics; Somatic mutations
• Online Access: http://link.springer.com/article/10.1007/s40487-018-0090-6
• ISSN: 2366-1070; 2366-1089

Abstract Cancer pharmacogenomics is the science concerned with understanding genetic alterations and its effects on the pharmacokinetics and pharmacodynamics of anti-cancer drugs, with the aim to provide cancer patients with the precise medication that will achieve a good response and cause low/no incidence of adverse events. Advances in biotechnology and bioinformatics have enabled genomic research to evolve from the evaluation of alterations at the single-gene level to studies on the whole-genome scale using large-scale genotyping and next generation sequencing techniques. International collaborative efforts have resulted in the construction of databases to curate the identified genetic alterations that are clinically significant, and these are currently utilized in clinical sequencing and liquid biopsy screening/monitoring. Furthermore, countless clinical studies have accumulated sufficient evidence to match cancer patients to therapies by utilizing the information of clinical-relevant alterations. In this review we summarize the importance of germline alterations that act as predictive biomarkers for drug-induced toxicity and drug response as well as somatic mutations in cancer cells that function as drug targets. The integration of genomics into the medical field has transformed the era of cancer therapy from one-size-fits-all to cancer precision medicine.